Amicus Therapeutics (NASDAQ:FOLD) Given New $22.00 Price Target at UBS Group
Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its price target lifted by UBS Group from $21.00 to $22.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also recently weighed in on FOLD. Cantor Fitzgerald restated an “overweight” […]
Amicus Therapeutics (NASDAQ:FOLD – Free Report) had its price target lifted by UBS Group from $21.00 to $22.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other research firms have also recently weighed in on FOLD. Cantor Fitzgerald restated an “overweight” […]
